Adjusted Indirect Treatment Comparison of Progression-Free Survival with D-Rd and VRd Based on MAIA and SWOG S0777 Individual Patient-Level Data
ConclusionThis anchored ITC demonstrated a greater PFS benefit for D-Rd versus VRd in TIE patients with NDMM. In the absence of head-to-head trials comparing D-Rd and VRd, the present trial may help inform treatment selection in this patient population. (Source: Advances in Therapy)
Source: Advances in Therapy - March 18, 2024 Category: Drugs & Pharmacology Source Type: research
Treatment-emergent mutations in myelodysplastic syndrome with del(5q) – lenalidomide related or disease-intrinsic clonal evolution?
Blood Cancer Journal, Published online: 18 March 2024; doi:10.1038/s41408-024-01027-5Treatment-emergent mutations in myelodysplastic syndrome with del(5q) – lenalidomide related or disease-intrinsic clonal evolution? (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - March 18, 2024 Category: Hematology Authors: Mostafa Abdallah Kaaren Reichard Naseema Gangat Ayalew Tefferi Source Type: research
Characteristics and outcomes of patients with relapsed/refractory multiple myeloma after exposure to lenalidomide in first line of therapy: a single center database review in greece
Most patients with multiple myeloma (MM) will develop disease recurrence during first-line (1L) treatment and eventually to subsequent treatments. These patients become refractory to treatment (developing relapsed/refractory MM [RRMM]), with disease severity and duration of remission worsening with each successive relapse.1, 2 (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 18, 2024 Category: Hematology Authors: Efstathios Kastritis, Ioannis Ntanasis-Stathopoulos, Foteini Theodorakakou, Magdalini Migkou, Maria Roussou, Panagiotis Malandrakis, Nikolaos Kanellias, Evangelos Eleutherakis-Papaiakovou, Despina Fotiou, Vassiliki Spiliopoulou, Maria Gavriatopoulou, Sach Tags: Original Study Source Type: research
BCMA Directed Bispecific Antibody Induced Tumor Flare in Multiple Myeloma
A 53-year-old man with relapsed multiple myeloma presented with bilateral upper limb sensorimotor symptoms caused by an enlarging cervical spine (C3) tumoral lesion. His prior treatments included spinal surgery and radiotherapy (RT) 11 years earlier for solitary plasmacytoma, daratumumab bortezomib lenalidomide dexamethasone followed by high dose melphalan and autologous stem-cell transplantation and daratumumab + lenalidomide maintenance as first line therapy for systemic myeloma 4 years before current presentation. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 16, 2024 Category: Hematology Authors: Chandramouli Nagarajan, Martin Wong Eu Jo, Thomas G Martin Tags: Letter to the Editor Source Type: research
Cancers, Vol. 16, Pages 1166: Mezigdomide & mdash;A Novel Cereblon E3 Ligase Modulator under Investigation in Relapsed/Refractory Multiple Myeloma
Cancers, Vol. 16, Pages 1166: Mezigdomide—A Novel Cereblon E3 Ligase Modulator under Investigation in Relapsed/Refractory Multiple Myeloma
Cancers doi: 10.3390/cancers16061166
Authors:
Monique A. Hartley-Brown
Clifton C. Mo
Omar Nadeem
Shonali Midha
Jacob P. Laubach
Paul G. Richardson
Mezigomide is an oral cereblon E3 ligase modulator (CELMoD) that is under clinical investigation in patients with relapsed/refractory (RR) multiple myeloma (MM). Like other CELMoD compounds, mezigdomide acts by altering the conformation of cereblon within the cullin 4A ring ligase–cereblon (CRL4CRBN) ...
Source: Cancers - March 15, 2024 Category: Cancer & Oncology Authors: Monique A. Hartley-Brown Clifton C. Mo Omar Nadeem Shonali Midha Jacob P. Laubach Paul G. Richardson Tags: Review Source Type: research
Toripalimab plus lenalidomide for central nervous system recurrence in refractory CD5(+) diffuse large B-cell lymphoma with MYD88 and CD79B comutation: a case report
CONCLUSIONS: These findings suggest that toripalimab may be a new therapeutic option for central nervous system recurrence in refractory CD5+ DLBCL with MYD88 and CD79B comutation. Further clinical trials are warranted to confirm these results.PMID:38482415 | PMC:PMC10928622 | DOI:10.21037/tcr-23-1638 (Source: Cell Research)
Source: Cell Research - March 14, 2024 Category: Cytology Authors: Xi Chen Zhihan Zhang Junbao Zhang Qiuxiao Yu Junjing Qiu Yajie Xiao Binbin Chen Ping Xu Source Type: research
A single ‐centre, real‐world study of BTK inhibitors for the initial treatment of MYD88mut/CD79Bmut diffuse large B‐cell lymphoma
ConclusionThis study suggests that newly diagnosed DLBCL patients with MYD88mut and/or CD79Bmut may benefit from BTKis according to real-world clinical data. (Source: Cancer Medicine)
Source: Cancer Medicine - March 8, 2024 Category: Cancer & Oncology Authors: Ting Deng,
Shiyuan Zhang,
Min Xiao,
Jia Gu,
Liang Huang,
Xiaoxi Zhou Tags: RESEARCH ARTICLE Source Type: research
A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for Bruton's tyrosine kinase inhibitors (BTKis) single and its combination therapy
CONCLUSIONS: The Ibrutinib-Obinutuzumab combo has the highest risk of infection, atrial fibrillation and myelosuppression, the Ibrutinib-Lenalidomide combo has the highest risk of pyrexia. However, the Ibrutinib-Venetoclax combo has a lower risk of hemorrhage than monotherapy.PMID:38456691 | DOI:10.1080/14740338.2024.2327507 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - March 8, 2024 Category: Drugs & Pharmacology Authors: Sichun Xiang Rongbin Shen Jingjing Xiang Ni Zhu Jianyou Gu Jianping Shen Yu Zhang Hangping Ge Source Type: research
A single-centre, real-world study of BTK inhibitors for the initial treatment of MYD88 < sup > mut < /sup > /CD79B < sup > mut < /sup > diffuse large B-cell lymphoma
CONCLUSION: This study suggests that newly diagnosed DLBCL patients with MYD88mut and/or CD79Bmut may benefit from BTKis according to real-world clinical data.PMID:38457222 | DOI:10.1002/cam4.7005 (Source: Cancer Control)
Source: Cancer Control - March 8, 2024 Category: Cancer & Oncology Authors: Ting Deng Shiyuan Zhang Min Xiao Jia Gu Liang Huang Xiaoxi Zhou Source Type: research
A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for Bruton's tyrosine kinase inhibitors (BTKis) single and its combination therapy
CONCLUSIONS: The Ibrutinib-Obinutuzumab combo has the highest risk of infection, atrial fibrillation and myelosuppression, the Ibrutinib-Lenalidomide combo has the highest risk of pyrexia. However, the Ibrutinib-Venetoclax combo has a lower risk of hemorrhage than monotherapy.PMID:38456691 | DOI:10.1080/14740338.2024.2327507 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - March 8, 2024 Category: Drugs & Pharmacology Authors: Sichun Xiang Rongbin Shen Jingjing Xiang Ni Zhu Jianyou Gu Jianping Shen Yu Zhang Hangping Ge Source Type: research
Cost-Effectiveness of Novel Agent Regimens for Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients in India
ConclusionAt the current WTP threshold of one-time per capita GDP ( ₹ 146,890) of India, VRd alone and VRd plus AHSCT has 38.1% and 6.9% probability to be cost-effective, respectively. Reduction in current reimbursement rates of novel drugs, namely VRd, lenalidomide, and pomalidomide plus dexamethasone under national insurance program and societal cost of transpla nt by 50%, would make VRd plus AHSCT and VTd plus AHSCT cost-effective at an incremental cost of ₹40,671 (US$34) and ₹97,639 (US$1,281) per QALY gained, respectively. (Source: Applied Health Economics and Health Policy)
Source: Applied Health Economics and Health Policy - March 7, 2024 Category: Health Management Source Type: research
